CCCC
USDC4 Therapeutics Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$2.350
最高
$2.420
最低
$2.290
交易量
1.58M
公司基本面
市值
225.3M
行業
生物科技
國家
United States
交易統計
平均交易量
1.92M
交易所
NMS
貨幣
USD
52週範圍
相關新聞
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Wells Fargo analyst Derek Archila maintains C4 Therapeutics with a Overweight and raises the price target from $5 to $10.
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics with a Overweight and maintains $6 price target.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics with a Overweight rating and announces Price Target of $8.
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics from Equal-Weight to Overweight and raises the price target from $3 to $6.
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
